Abstract:Event Abstract Back to Event The preparation of a t-PA/nanoparticle conjugate via bio-affinity ligation Xiaoli Liu1, Zengchao Tang1, Dan Li1* and Hong Chen1* 1 Soochow University, China Introduction: Tissue plasminogen activator (t-PA) is commonly used as a thrombolytic agent in the treatment of thrombotic diseases such as acute myocardial infarction and ischemic stroke. A major issue in the therapeutic use of t-PA is its very short half-life in the circulation (2–6 min) due to the effects of inhibitors, enzymes and antibodies in blood. Efforts have been made to overcome this deficiency by conjugating t-PA to synthetic materials to limit access of inhibitors or to materials with thrombus-targeted ability.[1] However, the linkages between t-PA and synthetic materials are commonly based on covalent bonding or electrostatic interactions, which are “invasive” and generally accompanied by loss of protein activity and immunogenic responses. Bio-affinity ligation based on the specific interactions between ligands and receptors has many advantages over covalent bonding and other nonspecific interactions for the conjugation of proteins to synthetic materials since it is benign to protein, highly specific and efficient, proceeds under physiological conditions and has no unwanted side reactions. Most proteins possess specific domains that can be recognized by some affinity ligand, so the interaction between such a domain and its affinity ligand can be utilized to link protein to materials. For t-PA, there is a high affinity lysine binding site in one of its two kringle domains that mediates its binding to carboxy-terminal lysine residues (ε-lysines) exposed on the surface of fibrin. Therefore ε-lysine is a natural affinity ligand that can be utilized to link t-PA to a synthetic material. Moreover, t-PA conjugated through ε-lysine mimics the one bound on the surface of fibrin in physiological fibrinolytic process, which is advantageous for limiting access of inhibitors. In this study, a t-PA/gold nanoparticle (t-PA/AuNP) conjugate was prepared via bio-affinity ligation. Materials and Methods: Here AuNPs were used as the model nanoparticles and modified with ε-lysine-terminated polyvinyl pyrrolidone (PVP), referred to as AuNPs-PVP-Lys. PVP functions as a bio-inert moiety to prevent the conjugate from interacting nonspecifically with other components in blood. t-PA was conjugated to AuNPs-PVP-Lys under physiological conditions through affinity interactions between ε-lysine exposed on AuNP surface and the specific domain in t-PA. Results and Discussion: Activity of the conjugated t-PA was compared with free t-PA both in vitro and in vivo. It is found that the t-PA/AuNP conjugate can not only maintain almost all enzyme activity of t-PA but also reduce the inhibition effect, leading to a prolonged circulation time (20.5 min). Conclusions: In conclusion, a t-PA/AuNPs-PVP-Lys conjugate was prepared under physiological conditions via bio-affinity ligation based on the bio-affinity interactions under physiological conditions. Compared with free t-PA, the conjugate retained almost full enzyme activity and clot-dissolving efficiency, and the t-PA was protected from inhibition by PAI-1 to some extent. Moreover, the conjugate showed prolonged circulation time in vivo. It will be of interest to apply this bio-affinity ligation more generally to conjugate synthetic materials with other proteins, especially those with important biomedical functions. National Natural Science Foundation of China (21204055, 21304062, 21334004); National Natural Science Foundation Fund for Distinguished Young Scholars (21125418); The Natural Science Foundation of the Jiangsu Higher Education Institutions of China (13KJB430020); China Postdoctoral Science Foundation (2013M541714)References:[1] X. Liu, L. Yuan, D. Li, Z. Tang, Y. Wang, G. Chen, H. Chen, J. L. Brash, J. Mater. Chem. B, 2014, 2, 5718-5738 Keywords: enzyme, nanoparticle, polymer Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: Poster Topic: Bioconjugates Citation: Liu X, Tang Z, Li D and Chen H (2016). The preparation of a t-PA/nanoparticle conjugate via bio-affinity ligation. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.01815 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. * Correspondence: Dr. Dan Li, Soochow University, Suzhou, China, lidan@suda.edu.cn Dr. Hong Chen, Soochow University, Suzhou, China, chenh@suda.edu.cn Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Xiaoli Liu Zengchao Tang Dan Li Hong Chen Google Xiaoli Liu Zengchao Tang Dan Li Hong Chen Google Scholar Xiaoli Liu Zengchao Tang Dan Li Hong Chen PubMed Xiaoli Liu Zengchao Tang Dan Li Hong Chen Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

A t-PA/nanoparticle conjugate with fully retained enzymatic activity and prolonged circulation time

The Preparation of a T-Pa/nanoparticle Conjugate Via Bio-Affinity Ligation

Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion

Thrombolytic Agents: Thrombosis-Responsive Thrombolytic Coating Based on Thrombin-Degradable Tissue Plasminogen Activator (t-PA) Nanocapsules (Adv. Funct. Mater. 45/2017)

Synthesis and characterization of positively charged tPA as a prodrug using a heparin/protamine-based drug-delivery system

Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots

A new t-PA releasing concept based on protein-protein displacement

Preparation and in vitro evaluation of tissue plasminogen activator-loaded nanoliposomes with anticoagulant coating

Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy

Interaction between tissue-type plasminogen activator and ligands grafted onto hydrogel

A Synergistic and Efficient Thrombolytic Nanoplatform: A Mechanical Method of Blasting Combined with Thrombolytic Drugs

TPA Immobilization on Iron Oxide Nanocubes and Localized Magnetic Hyperthermia Accelerate Blood Clot Lysis

Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers

RGD Modified Protein-Polymer Conjugates for Ph-Triggered Targeted Thrombolysis

Harnessing micrometer-scale tPA beads for high plasmin flux and accelerated fibrinolysis

Targeted Thrombolysis with Magnetic Nanotherapeutics: A Translational Assessment

Platelet-Mimic Upa Delivery Nanovectors Based on Au Rods for Thrombus Targeting and Treatment.

Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models

Thrombus Targeted Delivery of Urokinase and Ticagrelor for Thrombosis-related Diseases Treatment

Targeting of A Mutant Plasminogen Activator to Circulating Red Blood Cells for Prophylactic Fibrinolysis